首页> 外文期刊>Urology >Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy.
【24h】

Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy.

机译:前列腺癌根治性切除术后病理学上的自然器官受限史(pT2),格里森评分为6或更低。

获取原文
获取原文并翻译 | 示例
       

摘要

OBJECTIVES: Men with pathologically organ-confined, Gleason score 6 or less prostate cancer are considered to have an excellent prognosis after surgery as definitive monotherapy. We determined the incidence of biochemical recurrence (BR), local recurrence (LR), distant metastasis (DM), and prostate cancer-specific mortality (PCSM) among this low-risk cohort. METHODS: A retrospective search of our radical prostatectomy database identified 6081 men with pathologically organ-confined (pT2), Gleason score 6 or less prostate cancer treated from 1983 to 2005. Of these, 2551 (42%) had adequate follow-up information and were assessed for BR, LR, DM, and PCSM. The pathologic specimens of men with disease progression were reevaluated by an experienced genitourinary pathologist, and the patients with disease that was upgraded or upstaged (n = 25) were excluded from additional analysis, resulting in a final study cohort of 2526. The actuarial probabilities of BR and LR were estimated using the Kaplan-Meier method.RESULTS: With a median follow-up of 5.0 years (range 2 to 22), BR occurred in 13 patients (0.5%). The 5, 10, and 15-year actuarial probability of BR was 0.3%, 0.9%, and 1.3%, respectively. Five patients (0.2%) developed LR, four of whom received salvage radiotherapy with a subsequently undetectable prostate-specific antigen level. The 5, 10, and 15-year actuarial probability of LR was 0.1%, 0.5%, and 0.5%, respectively. No DM or PCSM occurred. CONCLUSIONS: With postoperative follow-up for more than 2500 patients with pathologically organ-confined, Gleason score 6 or less prostate cancer, BR and LR after radical prostatectomy were extremely rare, and no patients experienced DM or PCSM.
机译:目的:病理学上局限性,格里森评分不超过6分的前列腺癌患者,作为明确的单一疗法,在手术后被认为具有良好的预后。我们确定了该低危人群中生化复发(BR),局部复发(LR),远处转移(DM)和前列腺癌特异性死亡率(PCSM)的发生率。方法:回顾性研究我们的前列腺癌根治术数据库,确定了1983年至2005年接受治疗的6081名患有病理器官受限(pT2),Gleason评分为6以下的前列腺癌男性。其中2551名(42%)具有足够的随访信息,并且对BR,LR,DM和PCSM进行了评估。经验丰富的泌尿生殖系统病理学家对患有疾病进展的男性的病理标本进行了重新评估,并将疾病升级或升级的患者(n = 25)从其他分析中排除,最终研究队列为2526。结果:用Kaplan-Meier方法估计BR和LR。结果:中位随访时间为5.0年(范围2至22),BR发生在13例患者中(0.5%)。 BR的5年,10年和15年的精算概率分别为0.3%,0.9%和1.3%。五名患者(0.2%)发展为左室肥大,其中四名接受了挽救性放疗,其后未检测到前列腺特异性抗原水平。 LR的5年,10年和15年的精算概率分别为0.1%,0.5%和0.5%。没有发生DM或PCSM。结论:对超过2500名病理器官受限的患者进行了术后随访,Gleason评分6分或更低的前列腺癌,根治性前列腺切除术后的BR和LR极为罕见,并且没有患者经历DM或PCSM。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号